- AKT Tyrosine 176 Phosphorylation as Cancer Biomarker US Patent No. 8,557,516
Filed Date: February 8, 2010
Issue Date: October 15, 2013
pTyr176-AKT antibody (Hybridomas) is patented by Moffitt and has been licensed for commercial Cancer diagnostic kit
Title: Antibodies specific for phosphorylated histones and uses thereof
Patent No. 9,594,084 Filed Date: July 2, 2014 Issue Date: March 14, 2017 - European Patent No. EP 2 800 819 B
Issue Date: April 4, 2018
Published in the European Patent Bulletin No. 18/14
pHistone antibodies have also been licensed for commercialization - Methods for treatment of disorders related to phosphorylation of histones Application # 14/860,405
Filing Date: September 23, 2014
- Inhibitors of ACK1/TNK2 Tyrosine Kinase US Patent No 9,850,216
14833894.0 (European); 201480054401.3 (China); 201637004441 (India)
Filing Date: August 6, 2014
Issue Date: December 26, 2017
This technology has been licensed - Inhibitors of ACK1/TNK2 Tyrosine Kinase
Application # 15/748,214; 62/200,084; 62/299,178
Filing Date: August 2, 2016